Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Solifenacin or Mirabegron With Local Estrogen Versus Combination Treatment With Mirabegron and Solifenacin for Refractory Overactive Bladder

NCT06479720 is registered in ClinicalTrials.gov with Mackay Memorial Hospital as lead sponsor.

NCT NCT06479720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06479720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Solifenacin or Mirabegron With Local Estrogen Versus Combination Treatment With Mirabegron and Solifenacin for Refractory Overactive Bladder
Lead sponsor
Mackay Memorial Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
June 16, 2022
Completion date
December 31, 2026
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

effect of drug, urinary bladder, overactive